U.S. Point-of-Care Glucose Testing Market (By Product: Accu-Chek Inform II, Freestyle Lite, True Metrix, i-STAT, StatStrip, Onetouch Verio Flex, Bayer CONTOUR Blood Glucose Monitoring System) - Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2024-2033

U.S. Point-of-Care Glucose Testing Market Size and Growth

The U.S. point-of-care glucose testing market size was estimated at around USD 1.18 billion in 2023 and it is projected to hit around USD 1.84 billion by 2033, growing at a CAGR of 4.53% from 2024 to 2033.

Key Pointers

• By Product, the Accu-Chek Inform II generated the maximum market share of 19% in 2023.
• By Product, the FreeStyle Lite is anticipated to grow at the noteworthy CAGR from 2024 to 2033.

U.S. Point-of-Care Glucose Testing Market Overview

The U.S. point-of-care glucose testing market is witnessing significant growth driven by several factors including technological advancements, increasing prevalence of diabetes, and the growing demand for rapid and accurate diagnostic solutions. Point-of-care glucose testing refers to the analysis of glucose levels in blood samples at or near the location of patient care, providing immediate results to aid in timely decision-making by healthcare professionals.

U.S. Point-of-Care Glucose Testing Market Growth Factors

The growth of the U.S. point-of-care glucose testing market is propelled by an increasing prevalence of diabetes in the United States is a significant driver. With millions of Americans affected by the condition, there is a growing demand for efficient glucose monitoring solutions. Additionally, technological advancements play a crucial role in market expansion. Innovations in point-of-care glucose testing devices have improved their accuracy, speed, and user-friendliness, making them indispensable tools for healthcare professionals. Furthermore, the COVID-19 pandemic has underscored the importance of rapid diagnostics, further boosting the adoption of point-of-care testing solutions. These factors collectively contribute to the burgeoning growth of the U.S. point-of-care glucose testing market.

U.S. Point-of-Care Glucose Testing Market Trends:

• Expansion of Home Healthcare: Point-of-care glucose testing devices are increasingly being adopted for home use, enabling patients to monitor their glucose levels conveniently and facilitating remote patient management.
• Integration of Wireless Connectivity: Manufacturers are integrating wireless connectivity features into glucose testing devices, allowing for seamless data transfer to healthcare providers and electronic health records, thereby improving patient care and management.
• Shift Towards Personalized Medicine: There is a growing emphasis on personalized medicine and tailored treatment approaches for diabetes management, driving the development of advanced point-of-care testing solutions tailored to individual patient needs.
• COVID-19 Pandemic Impact: The COVID-19 pandemic has accelerated the adoption of point-of-care testing solutions, including glucose monitoring devices, to facilitate rapid diagnosis and decision-making in healthcare settings, further fueling market growth.
• Focus on User Experience: Manufacturers are increasingly focusing on enhancing the user experience by designing intuitive and user-friendly interfaces for point-of-care glucose testing devices, catering to the needs of both healthcare professionals and patients.

U.S. Point-of-Care Glucose Testing Market Restraints:

• Limited Reimbursement Policies: Inadequate reimbursement policies for point-of-care glucose testing devices may deter healthcare providers from adopting these technologies, particularly in underserved or economically disadvantaged communities.
• Cost Constraints: The high initial cost of acquiring point-of-care glucose testing devices, along with ongoing expenses for consumables and maintenance, may limit their adoption, particularly in resource-constrained healthcare settings.
• Accuracy Concerns: Despite technological advancements, concerns regarding the accuracy and reliability of point-of-care glucose testing devices persist, potentially impacting patient trust and clinical decision-making.
• Limited Healthcare Infrastructure: In rural or remote areas with limited healthcare infrastructure, access to point-of-care glucose testing devices and related services may be restricted, hindering market penetration and adoption.
• Data Security and Privacy Issues: The integration of wireless connectivity features in point-of-care glucose testing devices raises concerns regarding data security and privacy, particularly in light of stringent healthcare regulations such as HIPAA.

Product Insights

In 2023, the Accu-Chek Inform II dominated the market with a significant market share of 19%. This product is specifically designed for in-vitro diagnostic procedures aimed at monitoring blood glucose levels. The Accu-Chek Inform II glucose meter accurately measures blood glucose levels in various sample types including venous, capillary, whole blood, and even neonatal and arterial samples. Its widespread adoption among healthcare professionals is attributed to its role as a bedside monitoring solution, facilitating swift determination of glucose levels and streamlining the management of data generated by blood glucose tests. This functionality ultimately enhances the quality of patient care.

Meanwhile, the FreeStyle Lite, manufactured by Abbott, is poised to experience the most rapid growth throughout the forecast period. Recognized for its discreet size and user-friendly features, such as an embedded backlight and port light, the FreeStyle Lite caters particularly well to patients with busy lifestyles. This device enables the convenient determination of blood glucose levels from samples collected from various body locations including the fingers, upper arm, forearm, hand, and thigh.

U.S. Point-of-Care Glucose Testing Market Key Companies

• F. Hoffmann-La Roche Ltd.
• Abbott
• Nipro
• Platinum Equity Advisors, LLC (Lifescan, Inc.)
• Nova Biomedical
• ACON Laboratories
• Trividia Health, Inc.
• Prodigy Diabetes Care, LLC
• Bayer AG/Ascensia Diabetes Care Holdings AG
• EKF Diagnostics

Recent Developments

• In January 2024, Roche made headlines with its acquisition of LumiraDx's point-of-care technology, sealing the deal at a valuation surpassing USD 350 million. This strategic move granted Roche access to a diverse array of clinical chemistry and immunoassay tests, with the potential to introduce additional high-value medical tests in the years ahead.
• In February 2023, Insulet Corporation bolstered its portfolio by acquiring the assets of Automated Glucose Control LLC (AGC), a specialist in automated insulin delivery technology. Through this acquisition, Insulet set its sights on significant advancements in the development of automated insulin delivery technology.

U.S. Point-of-Care Glucose Testing Market Segmentation:

By Product

• Accu Check Aviva Meter
• Onetouch Verio Flex
• i-STAT
• Freestyle Lite
• Bayer CONTOUR Blood Glucose Monitoring System
• True Metrix
• Accu-Chek Inform II
• StatStrip
• Others